Cagrilintide vs Semaglutide: A Research Comparison

Cagrilintide and semaglutide are two long-acting, once-weekly injectable peptides that appear together constantly in the metabolic research literature, yet they act on entirely different receptor systems. Researchers, students, and readers following the obesity-pharmacology field often search this comparison to understand why the two are so frequently studied side by side and, increasingly, combined into a single therapy.

This article compares cagrilintide, an investigational long-acting amylin analogue, with semaglutide, an approved GLP-1 receptor agonist, on mechanism, pharmacokinetics, regulatory standing, and the depth of published evidence behind each.

Research-only notice. This is an educational reference. Both compounds are discussed here strictly in the context of laboratory and clinical research. Cagrilintide is an investigational agent not approved for general human use. Nothing here is medical advice, a dosing recommendation, or an endorsement of any product or supplier.

Mechanism of action

The compounds differ at the most fundamental level: they engage separate hormone systems. Semaglutide is an analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone. It binds and activates the GLP-1 receptor, which in pancreatic beta cells enhances insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and acts on central appetite-regulating circuits. Its protraction is engineered through three structural changes described by Knudsen and Lau: an alpha-aminoisobutyric acid substitution at position 8 that resists DPP-4 degradation, an arginine substitution at position 34, and a C18 fatty di-acid chain that binds albumin and slows renal clearance (PMID 31031702).

Cagrilintide instead mimics amylin (islet amyloid polypeptide), a hormone co-secreted with insulin by pancreatic beta cells. It behaves as a dual amylin and calcitonin receptor agonist, acting at amylin receptors formed when the calcitonin receptor complexes with receptor activity-modifying proteins (RAMP1/2/3). Through these receptors it drives satiety signaling in the brain, delays gastric emptying, and suppresses postprandial glucagon. Its design as a stable, lipidated long-acting analogue extending the half-life to roughly one week was reported by Kruse and colleagues (PMID 34288673).

The practical consequence is complementarity rather than redundancy. Amylin and GLP-1 signaling converge on appetite and gastric emptying but through distinct, parallel pathways, which is the rationale for studying them together.

Evidence and development status

Semaglutide is the far more mature molecule. It reached the market first for type 2 diabetes (2017), then in an oral formulation, and at a higher subcutaneous dose for chronic weight management. In the STEP 1 trial, once-weekly semaglutide 2.4 mg produced mean weight loss of about 14.9% over 68 weeks in adults with overweight or obesity without diabetes (Wilding et al., PMID 33567185). It is also the first agent of its kind supported by a dedicated cardiovascular outcomes trial: SELECT reported a roughly 20% reduction in major adverse cardiovascular events in people with overweight or obesity and established cardiovascular disease but without diabetes (Lincoff et al., PMID 37952131). This combination of weight, glycemic, and outcome data gives semaglutide an evidence base cagrilintide does not yet have.

Cagrilintide remains investigational. In a Phase 2 dose-finding trial, once-weekly cagrilintide monotherapy produced dose-dependent mean weight reductions of roughly 6.0% to 10.8% versus 3.0% with placebo over 26 weeks (Lau et al., PMID 34798060). Much of its momentum comes from combination research: an early Phase 1b study of cagrilintide co-administered with semaglutide 2.4 mg established feasibility and tolerability (Enebo et al., PMID 33894838). That pairing, known as CagriSema, advanced into the Phase 3 REDEFINE program, where the co-administered combination produced an estimated mean weight change of about -20.4% versus -3.0% with placebo at 68 weeks (Garvey et al., PMID 40544433). Notably, in the same trial family the combination outperformed either component alone, consistent with the additive-pathway hypothesis.

Research context

Both molecules are lipidated peptides engineered for albumin binding and weekly dosing, so their pharmacokinetic profiles look similar on paper. The scientific interest diverges in how they are typically studied. Semaglutide is frequently the comparator or backbone in metabolic trials because of its established efficacy and safety record, and its research now extends into cardiovascular, hepatic, and other end-organ questions. Cagrilintide is studied more as an emerging mechanism and as a partner molecule, with amylin biology attracting renewed attention as a complement to incretin therapy. Gastrointestinal effects such as nausea are commonly reported research observations for both classes and feature in the tolerability analyses of each program.

Key differences

• Receptor system: cagrilintide targets amylin (calcitonin/RAMP) receptors; semaglutide targets the GLP-1 incretin receptor.
• Approval: semaglutide is approved and widely marketed; cagrilintide is investigational and not approved anywhere.
• Evidence depth: semaglutide has a large Phase 3 program plus cardiovascular outcome data; cagrilintide’s standalone evidence is earlier-stage.
• Glucose handling: semaglutide directly stimulates glucose-dependent insulin release; cagrilintide’s metabolic effects run mainly through satiety, gastric emptying, and glucagon suppression.
• Combination role: the two are being developed together (CagriSema), where dual pathway activation has shown greater weight reduction than either alone.

Which for what research?

For research framed around a well-characterized, approved GLP-1 mechanism with the deepest available human data, including glycemic and cardiovascular endpoints, semaglutide is the reference compound. For investigators exploring amylin-receptor pharmacology, appetite and satiety pathways distinct from incretins, or combination strategies that stack complementary mechanisms, cagrilintide is the compound of interest, with the understanding that it remains experimental and its long-term profile is still being defined. The most active area at present is the intersection of the two: studying them together to test whether parallel amylin and GLP-1 signaling yields effects beyond either pathway alone. Selection in any legitimate setting should follow the specific research question, the maturity of the evidence, and applicable institutional and regulatory requirements, not the framing of this article.

Put these side by side in the Compare Peptides tool.

Sources

• Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021. PMID 34288673
• Lau DCW, et al. Once-weekly cagrilintide for weight management: a dose-finding phase 2 trial. Lancet. 2021. PMID 34798060
• Enebo LB, et al. Cagrilintide co-administered with semaglutide 2.4 mg: a phase 1b trial. Lancet. 2021. PMID 33894838
• Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019. PMID 31031702
• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID 33567185
• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. PMID 37952131
• Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025. PMID 40544433